Companies
Syngene International
Integrated safety assessment — BMS collaboration extended to 2035; PDE/HBEL toxicology; research CRDMO.
- Country
- India
Commercial
Public (BSE/NSE: SYNGENE)
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| bioinformatics-omics | ✓ | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | $195M (Historical) | intuitionlabs.ai |
| Capacity | 50,000L total single-use bioreactor capacity for large molecule services | biocon.com · bseindia.com · syngeneintl.com |
| Certification | ISO 9001:2015, ISO 14001:2015, ISO 45001:2018, ISO 13485:2016, ISO/IEC 27001:2022, ISO 15189:2012, GLP, NABL, CAP, AAALAC, and 5S certification | biocon.com · bseindia.com |
| Regulatory approval | US FDA, EMA, UK VMD, Health Canada, PMDA, MHRA, AGES, ANVISA, and CDSCO approved/inspected facilities | bseindia.com · syngeneintl.com |
| Production site | Bengaluru (India), Mangaluru (India), Hyderabad (India), and Baltimore (USA) | biocon.com · bseindia.com |
| Headcount | 8,235 employees (including over 5,600 scientists) | biocon.com · bseindia.com |
| Revenue | Rs. 37,387 million (FY26) | bseindia.com · syngeneintl.com |
Independent sources: biocon.com · bseindia.com · intuitionlabs.ai
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Toxics screening (toxicomics, service) | bioinformatics-omics | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.